WellStar Clinical Partners ACO Quality Measures Tip Sheet

|  |  |
| --- | --- |
| **Measure** | **ACO/MIPS QUALITY MEASURES TIP SHEET FOR CALENDAR YEAR 2024:****Documentation needed in chart to validate completed quality measures (Asterisked (\*) items can be documented by any member of the treatment team.)** |
|  ACO-13 (Care-2):**Screen for Future Fall Risk** (Pts aged 65 or older) | ⃝ Evidence that the patient has been asked, “have you had any falls/falls with injury in the year 2024?”\* OR a completed fall screening tool in chart, as long as it addresses any falls/falls with injury, especially within CY2024\* or gait or balance assessed during measurement period⃝ Statement of “no falls” meets the measure |
| ACO-20 (Prev-5):**Screen for Breast Cancer** (Women aged 40-74 Years) | ⃝ Mammogram report in chart, including date/results, OR provider note in chart stating that mammogram has been done, including date/results, between Oct. 1, 2022 and Dec. 31, 2024⃝ Patient reported data is acceptable as long as it includes full date (M/D/Y), type of test and results are documented in the chart⃝ Excluded: women with hx of bilateral or two unilateral mastectomies |
| ACO-19 (Prev-6):**Screen for Colorectal** Cancer (Pts aged 45-75 years) | ⃝ Screening date and result must be documented in the chart, either by final report/lab result, physician note, or patient reported data including full date of type of test (M/D/Y) and result (minimally documented as “normal” or “abnormal”) for any of the following tests:* FOBT during calendar year 2024 OR
* FIT-DNA screening/Cologuard between Jan. 1, 2022 and Dec. 31, 2024 OR
* Flexible sigmoidoscopy between Jan. 1, 2020 & Dec. 31, 2024 OR
* Colonoscopy between Jan. 1, 2015 & Dec. 31, 2024 OR
* CT Colonography between Jan. 1, 2020 and Dec. 31, 2024
 |
| ACO-14 (Prev-7):**Flu Vaccine** | ⃝ Evidence of flu immunization given between August 2023 and March 31, 2024 along with flu immunization August 2024 and December 2024 (current/most recent flu season)\* (Pt/caregiver reported information meets the measure) |
| ACO-17 (Prev-10):**Tobacco Use & Quit Advice 12 years & Older** | ⃝ Patient was screened for **tobacco use** (not just smokers) one or more times in CY2024⃝ ***IF*** a tobacco user (smoking, pipe, smokeless tobacco “chewing tobacco”) found on most recent screening, documentation of brief cessation counseling (3 minutes or less), and/or pharmacotherapy completed. Cessation is during the measurement period or 6 months prior to the measurement period. |
| ACO-18 (Prev-12)**Depression Screen & Follow Up** | ⃝ MUST include the name of screening tool used (Wellstar Epic uses PHQ2/PHQ9/PHQ-A)\*⃝ Patients screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter⃝ If screen is positive, follow up must be documented and must include at least one of the following:\** Referral to a practitioner who is qualified to diagnose & treat depression
* Pharmacological interventions
* Other interventions or follow-up for the dx & tx of depression
* ***Exclusion: Bipolar Diagnosis or Patient Refuse to complete or Medical reason for not screening (must be documented in note)***
 |
| ACO-42 (PREV-13):**Statin Therapy for the Prevention and Treatment of Cardiovascular Disease** |  ⃝ For a patient in any one of the four categories listed below, there is documentation that the  patient was prescribed or was already on statin medication therapy during calendar year 2024:1. All patients who were previously diagnosed with or currently have an

active diagnosis of clinical atherosclerotic cardiovascular disease1. Adult patients aged 20 to 75 years who have ever had a LDL-C level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia
2. Patients aged 40 to 75 years with a diagnosis of diabetes.
3. Patients aged 40 to 75 years at the beginning of the measurement period with a 10- year ASCVD risk score of >20 percent during the measurement period.
* ***EXCEPTIONS for Statin use:***
* ***Statin -associated muscle symptoms (SAMS) or allergy to statin medication***
* ***Active liver disease or hepatic disease or insufficiency***
* ***Documentation of a medical reason for not being prescribed statin therapy***
 |
| ACO-27 **Diabetes H A1c****Poor Control** (>9%) Pts aged 18-75 years | ⃝ If patient has diabetes, Hemoglobin A1c has been completed within CY2023⃝ Looks for levels >9% (“Reverse” measure – Lower numbers are better) |
| ACO-28 (HTN-2)**Controlling HBP in pts. With hypertension** (age 18-85 years of age) | ⃝ Diagnosis of essential hypertension starting before and continuing into or starting during the first six months of the measurement period (1/1/2024- 6/30/2024).⃝ BP recorded at most recent office visit during calendar year 2024\* *-- For Telehealth visits, example documentation “patient-reported BP via a home device during telehealth visit.”*⃝ “Controlled” for this measure is <140 systolic AND <90 diastolic |
| ACO-40 (MH-1): **For pts.****With Depression: Remission at 12 (+/- 60 days) Months** | ⃝ If patient has a documented PHQ9 score of > 9 between November 1, 2022 and October 31, 2023, this measure then looks for:⃝ Documented PHQ9 score of < 5 between 10 and 14 months after the initial PHQ9 score of >9.* ***EXCLUSIONS include patients with a diagnosis of bipolar disorder***
* ***EXCEPTIONS include*** documentation of medical reason for not screening for depression (cognitive, functional, or motivational limitations, etc.)
 |

WellStar Clinical Partners ACO; Revised 01.26.2024